Is 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure? Is 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure safe for nursing mother and child? Does 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure extracts into breast milk? Does 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure has any long term or short term side effects on infants? Can 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure influence milk supply or can 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure decrease milk supply in lactating mothers?

Some published studies indicate that 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure is not excreted into breast milk. A short half life and low oral bioavailability are characteristics that suggest it is the safest quinolone-type antimicrobial to be used while breastfeeding. Quinolone antibiotics are being used to treat infection in newborn infants without side effect reported. A small amount pass into breast milk but absorption by the child's gut is thought would be interfered by the calcium present in the milk. Should Fluor-quinolone medication be used in breastfeeding mothers, Nofloxacin, Ofloxacin and Ciprofloxacin are considered to be of choice because a lower concentration in mother's serum. Follow-up of the child for the appearance of diarrhea is recommended since one case of Colitis pseudomembranosa occurred in a breastfed child who was born premature and complicated with Necrotizing Enterocolitis. Consider the possibility of false negative results of urine cultures among breastfed infants from treated mothers who are febrile.

No information is available on the clinical use of 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure during breastfeeding; however, amounts in breastmilk appear to be low. Fluoroquinolones such as 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure have traditionally not been used in infants because of concern about adverse effects on the infants' developing joints. However, recent studies indicate little risk.[1][2] In addition, the calcium in milk might prevent absorption of the small amounts of fluoroquinolones in milk,[3] but insufficient data exist to prove or disprove this assertion. The serum and milk levels and oral bioavailability of 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure are the lowest of any of the fluoroquniolones, so the risk to the infant should be minimal. Use of 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure is acceptable in nursing mothers with monitoring of the infant for possible effects on the gastrointestinal flora, such as diarrhea or candidiasis (thrush, diaper rash).